Hinamizawa Syndrome: Difference between revisions
Content added Content deleted
No edit summary |
|||
Line 6: | Line 6: | ||
Shortly after Hifumi Takano's death, his adopted granddaughter, [[Miyo Takano]], took over the research of HS. She managed to secure generous funds from [["Tokyo"]] official named [[Nomura]]. Using this money, Miyo joined with [[Kyousuke Irie]] and formed the [[Irie Institution]] and further research HS from within [[Hinamizawa]] itself. |
Shortly after Hifumi Takano's death, his adopted granddaughter, [[Miyo Takano]], took over the research of HS. She managed to secure generous funds from [["Tokyo"]] official named [[Nomura]]. Using this money, Miyo joined with [[Kyousuke Irie]] and formed the [[Irie Institution]] and further research HS from within [[Hinamizawa]] itself. |
||
⚫ | |||
{{anchor|H-173}} |
{{anchor|H-173}} |
||
⚫ | |||
[["Tokyo"]] decided Japan needed a threatening biological weapon to compete with the emergent nuclear powers. As a result, "Tokyo" commissioned research for both the cure and infliction of HS. In 1980, [[Miyo Takano]] developed '''H-173''', a drug designed to induce L5 symptoms on any infected person. In 1983, H-173 is used in the assassination of [[Jirou Tomitake]]{{ref|notallarcs}}. |
[["Tokyo"]] decided Japan needed a threatening biological weapon to compete with the emergent nuclear powers. As a result, "Tokyo" commissioned research for both the cure and infliction of HS. In 1980, [[Miyo Takano]] developed '''H-173''', a drug designed to induce L5 symptoms on any infected person. In 1983, H-173 is used in the assassination of [[Jirou Tomitake]]{{ref|notallarcs}}. |
||